NeuroSens will be providing daily coverage of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 annual meeting, to be held September 18-20, 2024. You can help us fine-tune our reporting by completing the survey below. Thank you! Read More
Latest News
Meta-analysis of CBD meta-analyses reports efficacy in younger patients with seizure disorders
August 26, 2024A meta-analysis of 13 meta-analyses reports that cannabidiol (CBD) is effective for children and adolescents with seizures related to Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS) and tuberous sclerosis complex (TSC) (Borowicz-Reutt et al. Molecules 2024;29:1981). Read More
Does MS burn out?
August 20, 2024‘Burned-out MS’ (BOMS) is a term that has arisen recently in the multiple sclerosis literature. An early definition of BOMS described patients with a high EDSS score after a prolonged course of illness who had atrophy but no inflammatory activity on MRI (Bhatia & Singh. Ann Indian Acad Neurol 2019;22:131-136). The MS Association of America described BOMS as a form of inactive MS in which disease progression slows dramatically later in life. This is not a new phenotype since these definitions overlap with that of stable disease (not active/without progression) in the 2013 revisions (Lublin et al. Neurology 2014;83:278-286). The key difference and controversy is that BOMS presumes that no further MS-related progression will occur. Read More
What is the seizure risk after stopping antiseizure medications?
August 5, 2024Most patients with epilepsy become seizure-free during treatment with antiseizure medications (ASM) and current guidelines by the American Academy of Neurology (AAN) support ASM discontinuation in some individuals to reduce the side effect burden and improve quality of life (Gloss et al. Neurology 2021;97:1072-1081). Read More